Cholesterol and the Biology of Alzheimer's Disease

Recent results implicating cholesterol metabolism in the pathophysiology of Alzheimer's disease (AD) bring cholesterol to the forefront of AD research. Research from genetics, epidemiology, and cell biology all converge, suggesting that cholesterol plays a central role in the biology of amyloid precursor protein and the toxic peptide generated by its cleavage, beta-amyloid (Abeta). The ability of cholesterol to modulate Abeta production suggests opportunities for therapeutic intervention, although the functional significance underlying the connection between cholesterol and Abeta remains to be investigated.

[1]  J. Buxbaum,et al.  Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide. , 2001, The international journal of neuropsychopharmacology.

[2]  A. Tall,et al.  Expression of Liver X Receptor Target Genes Decreases Cellular Amyloid β Peptide Secretion* , 2003, Journal of Biological Chemistry.

[3]  D. Russell.  The enzymes, regulation, and genetics of bile acid synthesis. , 2003, Annual review of biochemistry.

[4]  N. Hooper,et al.  Exclusively targeting β-secretase to lipid rafts by GPI-anchor addition up-regulates β-site processing of the amyloid precursor protein , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Dichgans,et al.  Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26‐week randomized, placebo‐controlled, double‐blind trial , 2002, Annals of neurology.

[6]  Vicki Olm,et al.  Statin therapy for Alzheimer’s disease , 2002, Journal of Molecular Neuroscience.

[7]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[8]  S. DeKosky,et al.  22R-Hydroxycholesterol and 9-cis-Retinoic Acid Induce ATP-binding Cassette Transporter A1 Expression and Cholesterol Efflux in Brain Cells and Decrease Amyloid β Secretion* , 2003, The Journal of Biological Chemistry.

[9]  Arto Mannermaa,et al.  Apolipoprotein E 4 Allele, Elevated Midlife Total Cholesterol Level, and High Midlife Systolic Blood Pressure Are Independent Risk Factors for Late-Life Alzheimer Disease , 2002, Annals of Internal Medicine.

[10]  C. Bergmann,et al.  Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Navarro-Antolín,et al.  Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. , 1998, The Journal of clinical investigation.

[12]  S. DeKosky,et al.  Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer's disease , 2002, Neuroscience Letters.

[13]  E. Kojro,et al.  Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  B. Hyman,et al.  Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid β-peptide , 2001, Nature Cell Biology.

[15]  G. Celesia,et al.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.

[16]  V. Álvarez,et al.  Variation in the LRP-associated protein gene (LRPAP1) is associated with late-onset Alzheimer disease. , 2001, American journal of medical genetics.

[17]  Rong Wang,et al.  Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model , 2000, Neurobiology of Disease.

[18]  R. Nitsch,et al.  ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer’s disease , 2003, Neurobiology of Aging.

[19]  G. Vega,et al.  Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. , 2003, Archives of neurology.

[20]  W. Maier,et al.  Association of the C766T polymorphism of the low‐density lipoprotein receptor‐related protein gene with Alzheimer's disease , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[21]  H Jick,et al.  Statins and the risk of dementia , 2000, The Lancet.

[22]  S. Younkin,et al.  Cholesterol-Dependent γ-Secretase Activity in Buoyant Cholesterol-Rich Membrane Microdomains , 2002, Neurobiology of Disease.

[23]  M. Mercken,et al.  A Cholesterol-Lowering Drug Reduces β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease , 2001, Neurobiology of Disease.

[24]  F. Jessen,et al.  Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease , 2002, Molecular Psychiatry.

[25]  M. Mercken,et al.  Presenilin Redistribution Associated with Aberrant Cholesterol Transport Enhances β-Amyloid Production In Vivo , 2003, The Journal of Neuroscience.

[26]  G. Eckert,et al.  Differential effects of lovastatin treatment on brain cholesterol levels in normal and ApoE-deficient mice , 2001, Neuroreport.